Actively Recruiting
Phase II Study of LM-24C5
Led by LaNova Medicines Limited · Updated on 2026-02-04
130
Participants Needed
2
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to evaluate the efficacy and safety of the LM-24C5 in combination with other therapies in subjects with CEACAM5-positive advanced solid tumor
CONDITIONS
Official Title
Phase II Study of LM-24C5
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing to participate and sign informed consent
- Aged 18 to 80 years, male or female
- ECOG performance status of 0 or 1
- Life expectancy of at least 3 months
- Histological or cytological confirmation of recurrent or refractory advanced solid tumors or intolerance/lack of standard therapy
- CEACAM5-positive
- At least one measurable lesion
- Appropriate organ and marrow function within 7 days before first dose
- Ability to communicate well and follow study requirements
You will not qualify if you...
- History of other malignancies within 5 years except certain cured or low-risk cancers
- Received other anti-tumor treatments before first LM-24C5 dose
- Previous immunotherapy with severe immune-related adverse events or myocarditis
- Unresolved adverse events from prior anti-tumor therapy above grade 1
- Peripheral sensory or motor neuropathy grade 2 or higher
- Uncontrolled pain
- Untreated symptomatic central nervous system or meningeal metastases
- Uncontrollable third space effusion
- Prior targeted therapy for the same target
- Use of live vaccines within 28 days before first dose
- Interstitial lung disease or pneumonia needing glucocorticoids
- Use of anticoagulants like heparin or vitamin K antagonists
- Persistent uncontrollable vomiting
- Severe gastrointestinal bleeding, ulceration, or diarrhea within 28 days prior
- Major surgery or interventional treatment within 28 days prior
- Severe cardiovascular disease
- Uncontrolled or severe illness
- Use of systemic corticosteroids or immunosuppressive drugs within 2 weeks before first dose
- History of autoimmune diseases
- History of immunodeficiency
- HIV, active HBV, or HCV infection
- Positive pregnancy test or lactating females with child-bearing potential
- Psychiatric disorders affecting compliance
- Judged ineligible by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Fujian Cancer Hospital
Fuzhou, Fujian, China, 350014
Actively Recruiting
2
Shanghai East Hospital
Shanghai, Shanghai Municipality, China, 200123
Not Yet Recruiting
Research Team
M
Mengmeng Liu
CONTACT
P
Paul Kong
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here